Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis

BACKGROUND: Malignant melanoma is the most aggressive and deadly form of skin cancer. Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in routine clinical practice. However, response rates with single-agent DTIC are low. The objective of this study was to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Guan, Li, Rong-Hua, Sun, Chao, Liu, Yan-Qun, Zheng, Jun-Nian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263472/
https://www.ncbi.nlm.nih.gov/pubmed/25502446
http://dx.doi.org/10.1371/journal.pone.0111920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263472/
https://www.ncbi.nlm.nih.gov/pubmed/25502446
http://dx.doi.org/10.1371/journal.pone.0111920

Ejemplares similares